Eli Lilly Stock News

Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.

There's plenty out there that could potentially drive a broad market pullback, but there are also plenty of individual stocks due for a pullback. Irrespective how the market performs from here, these

Eli Lilly said on Monday that it will acquire a manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines.

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic

Eli Lilly and Novo Nordisk are two of the big names in healthcare focused on a hot GLP-1 drug market. But there's a drug from a smaller biotech which could also prove to be a big player in this area.

The findings add to concerns that GLP-1s could take a bite out of the bottom lines of some of the biggest restaurant companies and packaged food makers.

Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.

Super Micro Computer (SMCI), Eli Lilly (LLY), and Netflix (NFLX) are today's big three stocks. Joel Hawthorne and Ben Lichtenstein discuss how to trade, as well as the technical trends of these names.

When Wall Street tags a stock as a strong buy, it is probably right. Generally speaking, such shares tend to be among the best positioned investments in the market.

Looking ahead to the pharmaceutical earnings season, UBS expressed cautious optimism when looking at several major names. Notably, Eli Lilly and Co (NYSE:LLY), with a 'buy' rating and a price target

Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.

Tesla's transformation over the past 10 years has made it one of the most valuable stocks on Wall Street. The excitement around a highly promising weight-loss drug has made Eli Lilly a hot buy in rece

One of the pharmaceutical giant's hotter medications tested well for a new indication. It has already attracted much attention for the molecule being studied, as it's used in two FDA-approved treatmen

From diabetes to heart disease, the obesity drug Zepbound has been shown to have positive effects for other health ailments. Now, the company has a trial pointing to reduced sleep apnea severity.

Shares of Eli Lilly (LLY) gained in intraday trading Wednesday after the pharmaceutical firm said a late-stage study found its weight-loss drug, Zepbound, was effective in treating those who are overw